Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries WALTHAM, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...

WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public...

Bill Desmarais, Ph.D., MBA, named Chief Business Officer, bringing more than 20 years of business development and partnering experience Oncology drug development veteran Gabriela Gruia, M.D., appointed to Board of Directors Timothy Barberich named Chair of Board of Directors WALTHAM, Mass., May 27,...

WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Katina Dorton, J.D., M.B.A., to its...

WALTHAM, Mass. – TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) in oncology, today announced the appointment of Brian M. Silver as its Chief Financial Officer, effective May 2, 2021. Mr....

Funds and accounts managed by BlackRock and RA Capital Management join two other healthcare-focused funds and current investors. Proceeds to support continued development of TCR-T cell therapy pipeline WALTHAM, Mass. – (BUSINESS WIRE) – TScan Therapeutics, a biopharmaceutical company focused on the...

WALTHAM, Mass.–( BUSINESS WIRE )–TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors. Mr....

WALTHAM, Mass.–( BUSINESS WIRE )–TScan Therapeutics,   a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology,   today announced that David Southwell, Chief Executive Officer, will present virtually at the 39 th  Annual J.P....